Mirum Pharmaceuticals secures $68.5 million private placement with TCGX

Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) announced it entered into a subscription agreement with entities associated with TCGX for a private placement of 1 million shares of common stock at $68.48 per share, generating approximately $68.5 million in gross proceeds.

The proceeds from this private placement, combined with a previously announced $200 million private placement earlier this month, are intended to fund clinical development and commercial activities following the proposed acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases.

Both private placements are expected to close concurrently with the proposed Bluejay acquisition, which is anticipated in the first quarter of 2026, subject to regulatory approval and other customary closing conditions.

The securities are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933. The shares may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from registration requirements.

Mirum and the investors entered into a registration rights agreement that will become effective upon closing of the private placement. Under this agreement, Mirum has committed to file a registration statement with the Securities and Exchange Commission to register the resale of the shares sold in the private placement.

The information is based on a company press release statement.

You May Also Be Interested In

• Karman Line Acquisition closes $200M IPO on Nasdaq
• Nebius Group plans $4.5B convertible notes offering in two series
• QNB Corp. prices stock offering at $42 per share on Nasdaq